Quick Answer: A CDSCO licence carries no legal weight at FDA. There is no mutual recognition agreement between India and the United States for medical devices, and FDA grants clearance through a 510(k), not "approval" — the same distinction that trips up manufacturers coming from any foreign regime. What genuinely transfers is evidence, not status: if your quality system is ISO 13485-certified, it substantially aligns with FDA's Quality Management System Regulation (QMSR), effective since 2 February 2026. If your testing was performed by a NABL-accredited lab under ISO/IEC 17025, that accreditation is a real, internationally recognised quality signal — but FDA acceptance still turns on whether the test followed the FDA-recognised standard, not on which body accredited the lab. CDSCO's own four-class system doesn't map cleanly onto FDA's three classes, so classification has to be redone from scratch, and US Agent and establishment registration are required before US commercial distribution, not before 510(k) clearance.

CDSCO and FDA are answering different questions, not the same question twice

India regulates medical devices under the Medical Devices Rules, 2017 (MDR 2017), enforced by the Central Drugs Standard Control Organisation (CDSCO) under the Ministry of Health and Family Welfare. Devices are classified into four risk-based classes, A through D, with applications filed through the SUGAM portal — Form MD-14 or MD-15 for the application, resulting in a Form MD-5 or MD-6 licence depending on class, valid for five years.

None of that is recognised by FDA, and the reverse is equally true: holding FDA clearance does not accelerate or bypass CDSCO review for a device you also want to sell in India. Each regulator asks its own question about your device, using its own evidentiary standard, and answers only for its own market. The honest way to think about a CDSCO licence at FDA is the same way we've covered a CE Mark at FDA: not as a credential that transfers, but as a body of underlying evidence, some of which is reusable and some of which has to be rebuilt. If you hold both a CDSCO licence and a CE Mark, what a CE Mark is actually worth at FDA is the more developed version of this same question.

Why there's no shortcut: no MRA exists between CDSCO and FDA

This is worth stating plainly because it's the assumption that costs manufacturers the most time. There is no mutual recognition agreement between CDSCO and FDA for medical devices — no arrangement under which an inspection, audit, or clearance decision made by one is formally relied upon by the other.

Some industry reporting describes discussions around this changing over time — India has been an active participant in IMDRF harmonisation efforts, and at least one industry source describes exploratory work toward recognising MDSAP audit reports as evidence of quality system compliance. Treat that as a direction of travel, not a current mechanism. Nothing published confirms a working reliance arrangement is in force today. If you're planning around one, you're planning around a discussion, not a rule.

Worth noting: India's absence from formal international reliance frameworks isn't unique to its relationship with FDA. When WHO published its first list of transitional Listed Authorities for medical devices in July 2026, CDSCO was not among the twelve regulators named. FDA was. That's the same portability gap showing up in a second, independent framework.

Classification doesn't translate — it has to be redone

CDSCO's four classes (A, B, C, D) are risk-based, like FDA's three, but the boundaries are not identical, and there is no conversion table you can apply mechanically. A device that sits in CDSCO Class B is not automatically FDA Class II. Confirming US classification and product code is a first-principles exercise against FDA's own classification database and 21 CFR regulations — not a lookup against your existing CDSCO paperwork.

This matters because everything downstream depends on getting it right: applicable consensus standards, testing scope, and whether a predicate even exists all follow from the US classification, not the Indian one.

What genuinely transfers: your quality system, post-QMSR

Here the news is better, and it's the same structural shift we've covered for CE-marked manufacturers. The Quality Management System Regulation took effect on 2 February 2026 and incorporates ISO 13485:2016 by reference into 21 CFR Part 820. If your quality system is ISO 13485-certified — common among Indian manufacturers already exporting to the EU, Gulf, or ASEAN — that system now substantially aligns with what FDA expects. Our ISO 13485 guide and QMSR breakdown cover the mechanics in full; the short version that matters here is the same caution that applies to any foreign manufacturer: an ISO 13485 certificate is not accepted in lieu of an FDA inspection. An MDSAP audit report is accepted as a substitute for routine surveillance inspections. If you hold MDSAP — more common among manufacturers already selling into Canada — you hold something FDA acts on directly. If you hold only ISO 13485, you don't, yet.

NABL accreditation is real — but it isn't an FDA recognition pathway

This is the distinction most Indian manufacturers get slightly wrong, often because testing labs' own marketing blurs it.

NABL (the National Accreditation Board for Testing and Calibration Laboratories) accredits Indian labs under ISO/IEC 17025, and that accreditation is genuinely recognised internationally through the ILAC Mutual Recognition Arrangement, spanning over 100 countries. That's real, and it's valuable: it means a NABL-accredited lab's general technical competence, calibration traceability, and quality management have been independently verified.

What it is not is a formal FDA recognition scheme. FDA does not maintain a list of accredited foreign lab-accreditation bodies whose stamp guarantees acceptance of test data, the way MDSAP works for QMS inspections. What FDA actually evaluates is whether your testing was performed to the FDA-recognised version of the relevant standard — the ISO 10993 series for biocompatibility, IEC 60601 series for electrical safety and performance — on your finished device, with complete and traceable documentation. A NABL-accredited lab is well-positioned to produce exactly that kind of defensible data. The accreditation supports credibility; it doesn't substitute for checking that the specific tests, standard versions, and endpoints match what your predicate and product code require. Confirming that match, test by test, is a mapping exercise worth doing deliberately rather than assuming — it's the kind of gap analysis Complizen's Superagent platform is built to run against your actual file, rather than a general rule of thumb about what "should" transfer.

One additional domestic requirement worth tracking, separate from FDA entirely: certain devices must also comply with Bureau of Indian Standards (BIS) requirements under the Omnibus Technical Regulation, with the compliance deadline for BIS Scheme X Certification extended to 1 September 2026. This has no bearing on your FDA submission, but it's real near-term compliance load layered on top of CDSCO, and worth planning around if it applies to your device.

The predicate problem that hits Indian exporters harder than CE-marked ones

This is the sharpest strategic difference from the CE Mark version of this question, and it's worth naming directly rather than assuming your situation looks like a European manufacturer's.

CE-marked devices are frequently built on technology platforms that already have a foothold in mature, harmonised markets, so a reasonable US predicate often exists even before you go looking. Devices designed primarily for price-sensitive or domestic Indian and other emerging markets don't always have that lineage. Choosing the right predicate device is a strategic judgment call for any manufacturer, but for a device with no close US analogue, the predicate search can come up thin or empty — which changes the pathway question entirely rather than just the testing scope. If no adequate predicate exists, 510(k) isn't available to you, and De Novo becomes the relevant pathway instead of a fallback. Knowing which situation you're in before you scope testing is the single highest-leverage thing to get right early, and it's exactly the judgment call Complizen's regulatory strategy engagement is built to make before testing budgets are committed.

Two different "agents," two different regulators

A specific, avoidable confusion: CDSCO requires foreign manufacturers importing into India to appoint an Authorized Indian Agent. FDA requires foreign manufacturers to appoint a US Agent before commercial distribution in the United States. These are two separate roles, serving two separate regulators, and neither substitutes for the other. An Indian manufacturer exporting to the US needs a US Agent for FDA purposes regardless of any Indian agent arrangement already in place for CDSCO purposes. And as with any foreign manufacturer, US Agent designation and establishment registration are conditions of commercial distribution, not of 510(k) clearance — registering early, before you have anything to sell, starts an annual fee clock for no benefit.

What it costs at FDA in FY2027

FDA fees are the same for every manufacturer regardless of country of origin. In FY2027, running 1 October 2026 through 30 September 2027: a standard 510(k) is $28,653, or $7,163 with small business status; annual establishment registration is $13,785, with no small business reduction.

Foreign manufacturers, including Indian ones, qualify for small business status through a National Taxing Authority Certification rather than a US tax return — a certification bearing the official seal of the relevant national tax authority, confirming gross receipts in both local currency and US dollars. For an Indian applicant, that means engaging India's Income Tax Department for the certification well before the fee is due; FDA requires you to apply at least 60 days ahead, and states plainly it will not refund the difference if you file at the standard rate and qualify later. Wait for confirmation before you submit if the reduced fee matters to your budget.

Two clocks, not one

CDSCO reports risk-proportionate review targets — roughly 30 to 60 days for Class A and B devices, and 90 to 180 days for Class C and D, according to industry reporting on the current framework, treat these as directional rather than guaranteed. FDA's MDUFA V goals commit to a decision within 90 FDA days for 95% of 510(k)s. Neither timeline speeds up the other, and they don't run in sequence in any way that benefits you — clearing CDSCO first doesn't shorten your FDA review, and there's no combined clock to plan against. Budget them as two entirely independent projects, because that's what your regulators are treating them as.

It's also worth remembering that "FDA days" and calendar days aren't the same thing. FDA's clock pauses whenever it's waiting on you — most commonly during an Additional Information request — so a 90-day goal can stretch well beyond that in real elapsed time if a response takes weeks to prepare.

FDA doesn't grade on geography

Worth saying plainly, because it's the kind of thing manufacturers sometimes hope isn't quite true: FDA's enforcement posture toward foreign facilities has hardened in the past two years, not softened, and India is not exempted from that trend. Device-specific warning letter data from FDA's own enforcement actions shows the same violation categories — CAPA procedures, complaint handling, design controls — recurring across manufacturers regardless of country. Data integrity and documentation practices have drawn particular scrutiny at facilities in India specifically, per recent industry trend analysis of FDA actions. FDA also maintains a standing import alert allowing detention without physical examination of device shipments from firms that refuse a foreign establishment inspection — a real mechanism, not a hypothetical one.

None of this is a reason for alarm. It's a reason to treat your quality system as something that has to function in daily operation, not just read well on a NABL or CDSCO audit day — because FDA inspects operations, not documents.

Common mistakes

Assuming a CDSCO licence or ISO 13485 certificate accelerates FDA review. Neither does. What transfers is underlying evidence, evaluated on its own merits against FDA's requirements.

Treating NABL accreditation as FDA recognition. It's a real, internationally recognised quality signal — not a formal US regulatory reliance mechanism. FDA still evaluates the specific standard, version, and endpoints tested.

Confusing your CDSCO Authorized Indian Agent with an FDA US Agent. Two roles, two regulators, no substitution.

Assuming a predicate exists because your device sells well domestically. Devices built for price-sensitive markets sometimes have no close US analogue. Confirm this early — it determines whether 510(k) is even your pathway.

Registering your US establishment before you have a clearance or a buyer. It's a distribution requirement, not a submission requirement, and it starts an annual fee for no immediate benefit.

Frequently asked questions

Does a CDSCO licence help with FDA clearance? Not as a credential — there's no mutual recognition agreement between CDSCO and FDA, and a CDSCO licence has no legal standing at FDA. It helps indirectly, through the underlying evidence behind it: an ISO 13485-certified quality system aligns substantially with FDA's QMSR, and NABL-accredited testing carries real credibility, though FDA's acceptance still depends on the specific standard and version tested, not the accrediting body.

Is there a mutual recognition agreement between India and the US for medical devices? No. Industry reporting describes exploratory discussion around recognising MDSAP audits as part of broader IMDRF harmonisation efforts, but no formal reliance arrangement is currently in force. CDSCO also does not appear on WHO's July 2026 list of transitional Listed Authorities for medical devices, while FDA does.

Does NABL accreditation mean FDA will accept my test data? Not automatically. NABL accreditation under ISO/IEC 17025 is genuinely recognised internationally through the ILAC Mutual Recognition Arrangement, and it's a strong signal of a lab's technical competence. FDA acceptance, however, turns on whether the specific test followed the FDA-recognised standard and version for your device type, with complete documentation — not on which body accredited the lab performing it.

Do I need a US Agent if I already have an Authorized Indian Agent for CDSCO? Yes, separately. CDSCO's Authorized Indian Agent requirement and FDA's US Agent requirement serve two different regulators and are not interchangeable. Exporting to the US requires designating a US Agent regardless of your existing CDSCO agent arrangement.

What FDA classification does my CDSCO Class B device get? There's no direct conversion. CDSCO's four classes and FDA's three classes use different risk boundaries, so US classification has to be determined independently against FDA's own product code database and regulations, not inferred from your Indian classification.

How long does FDA clearance take after CDSCO approval? CDSCO approval doesn't shorten FDA review in any way. FDA's MDUFA V goal is a decision within 90 FDA days for 95% of submissions, measured independently of anything happening at CDSCO. Budget the two as separate timelines, not sequential ones.

What does FDA clearance cost for an Indian manufacturer? The same published fees as any manufacturer. In FY2027, a standard 510(k) is $28,653, or $7,163 with small business status, plus $13,785 for annual establishment registration. Foreign manufacturers, including those in India, qualify for small business status through a National Taxing Authority Certification from their national tax authority rather than a US tax return.

Does my device need a US predicate, or can I use my Indian market history? FDA requires demonstrating substantial equivalence to a legally marketed US predicate, not market history in India or elsewhere. If your device was built primarily for domestic or other emerging markets, a close US predicate may not exist, which can push your pathway toward De Novo rather than 510(k).

Is CDSCO on WHO's list of trusted regulators? No. CDSCO does not appear on WHO's July 2026 list of transitional Listed Authorities for medical devices, alongside several other major manufacturing-hub regulators. FDA does appear on that list.

Does FDA treat Indian manufacturing facilities differently during inspections? Not by design — FDA's stated standard is the same regardless of location. In practice, enforcement data shows the same violation categories recurring globally, with documentation and data integrity practices drawing particular scrutiny at facilities in India in recent trend reporting. The standard doesn't change; treating quality systems as operational reality rather than audit-day paperwork is what holds up under inspection.

Key takeaways

No credential shortcuts FDA. There's no MRA between CDSCO and FDA. What transfers is evidence — quality systems, test data — evaluated on its own merits, not status conferred by an Indian regulator.

QMSR is the genuine advantage, if you hold ISO 13485. Since February 2026, your quality system substantially aligns with FDA's expectations — though a certificate still isn't accepted in lieu of inspection the way an MDSAP report is.

NABL accreditation is real, but it isn't FDA recognition. It's a strong, internationally recognised quality signal. FDA acceptance still depends on the specific standard and version tested.

Predicate scarcity is a bigger risk for Indian exporters than for CE-marked manufacturers. Devices built for price-sensitive markets don't always have a close US analogue — confirm this before you scope testing, because it may change your pathway entirely.

CDSCO and FDA are two independent clocks. Neither timeline shortens the other. Plan them as separate projects with separate milestones.

Complizen helps international medical device manufacturers reach FDA 510(k) clearance, combining a software platform for in-house regulatory teams with full-service consultancy for teams without in-house FDA expertise.

Working out whether your predicate situation is straightforward or genuinely thin is the highest-leverage call to get right before you spend on testing. Complizen's regulatory strategy engagement maps your device to a US pathway, product code, and predicate shortlist, reviewed by a senior FDA expert. See how the strategy service works →

References

  1. CDSCO — Medical Devices Rules, 2017 (official text). https://cdsco.gov.in/opencms/opencms/en/Acts-and-rules/Medical-Devices-Rules/
  2. CDSCO — Medical Device & Diagnostics portal. https://cdsco.gov.in/opencms/opencms/en/Medical-Device-Diagnostics/
  3. FDA — Quality Management System Regulation (QMSR). https://www.fda.gov/medical-devices/postmarket-requirements-devices/quality-management-system-regulation-qmsr
  4. FDA — Medical Device Single Audit Program (MDSAP). https://www.fda.gov/medical-devices/cdrh-international-affairs/medical-device-single-audit-program-mdsap
  5. FDA — MDUFA Performance Goals and Procedures, Fiscal Years 2023 Through 2027. https://www.fda.gov/media/73507/download
  6. Federal Register — Medical Device User Fee Rates for Fiscal Year 2027. https://www.federalregister.gov/documents/2026/07/30/2026-15335/medical-device-user-fee-rates-for-fiscal-year-2027
  7. WHO — List of transitional WHO Listed Authorities for medical devices (tWLAs-MD), as of 1 July 2026 (PDF). https://cdn.who.int/media/docs/default-source/medicines/regulatory-systems/wla/list-of-transitional-wlas_md.pdf
  8. FDA — Import Alert 89-16: Detention Without Physical Examination of Products from Medical Device Firms Refusing FDA Foreign Establishment Inspection. https://www.accessdata.fda.gov/cms_ia/importalert_601.html
  9. NABL India — Accreditation programme and current notices. https://nabl-india.org/